Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01

Journal of Clinical Oncology

Volumn 28, Issue 1, 2010, Pages 21-28

  Machiels, Jean Pascal H ^a   Henry, Stéphanie ^a   Zanetta, Sylvie ^a   Kaminsky, Marie Christine ^a   Michoux, Nicolas ^a   Rommel, Denis ^a   Schmitz, Sandra ^a   Bompas, Emmanuelle ^a   Dillies, Anne Françoise ^a   Faivre, Sandrine ^a   Moxhon, Anne ^a   Duprez, Thierry ^a   Guigay, Joel ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CONTRAST MEDIUM; FLUOROURACIL; METHOTREXATE; SUNITINIB; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BLOOD TOXICITY; CANCER CONTROL; CANCER PALLIATIVE THERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; FEMALE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HEAD AND NECK CARCINOMA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOCALCEMIA; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SIDE EFFECT; SKIN DISEASE; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STOMACH HEMORRHAGE; THROMBOCYTOPENIA; THYROTROPIN BLOOD LEVEL; TUMOR BLEEDING; TUMOR BLOOD FLOW; VOMITING; HEAD AND NECK TUMOR; MAGNETIC RESONANCE ANGIOGRAPHY; MIDDLE AGED; PATHOLOGY; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; INDOLES; MAGNETIC RESONANCE ANGIOGRAPHY; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PYRROLES;

EID: 73949143686     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.23.8584     Document Type: Article

References (43)

1. Pisani P, Bray F, Parkin DM: Estimates of the world-wide prevalence of cancer for 25 sites in the adult population. Int J Cancer 97:72-81, 2002
2. Vokes EE, Weichselbaum RR, Lippman SM, et al: Head and neck cancer. N Engl J Med 328:184-194, 1993
3. Forastiere AA, Metch B, Schuller et al: Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 10:1245-1251, 1992
4. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
5. Neuchrist C, Erovic BM, Handisurya, et al: Vascular endothelial growth factor receptor 2 (VEGFR2) expression in squamous cell carcinomas of the head and neck. Laryngoscope 111:1834-1841, 2001
6. Neuchrist C, Erovic BM, Handisurya, et al: Vascular endothelial growth factor receptor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25:464-474, 2003
7. Riedel F, Gotte K, Schwalb J, et al: Serum levels of vascular endothelial growth factor in patients with head and neck cancer. Eur Arch Otorhinolaryngol 257:332-336, 2000
8. Kyzas PA, Cunha IW, Ioannidis JP: Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: A meta-analysis. Clin Cancer Res 11:1434-1440, 2005
9. Christensen JG: A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18:3-10, 2007 (suppl)
10. Demetri GD, van Osterom AT, Garrett CR, et al: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial. Lancet 368:1329-1338, 2006
11. Motzer RJ, Hutson TE, Tomczak P, et al: Sunitinib versus interferon alfa in metastatic renalcell carcinoma. N Engl J Med 356:115-124, 2007
12. Leon X, Hitt R, Constenla M, et al: A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinumbased chemotherapy. Clin Oncol (R Coll Radiol) 17:418-424, 2005
13. Stewart JS, Cohen E, Licitra L, et al: Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 27:1864-1871, 2009
14. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216, 2000
15. Michoux N, Huwart H, Abarca-Quinones J, et al: Transvascular and interstitial transport in rat hepatocellular carcinomas: Dynamic contrast-enhanced MRI assessment with low- and high-molecular weight agents. J Magn Reson Imaging 28:906-914, 2008
16. Larsson HB, Fritz-Hansen T, Rostrup E, et al: Myocardial perfusion modeling using MRI. Magn Reson Med 35:716-726, 1996
17. Tofts PS, Brix G, Buckley DL, et al: Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: Standardized quantities and symbols. J Magn Reson Imaging 10:223-232, 1999
18. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
19. Cohen EE, Rosen F, Stadler WM, et al: Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 21:1980-1987, 2003
20. Cohen EE, Kane MA, List MA, et al: Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Clin Cancer Res 11:8418-8424, 2005
21. Wheeler RH, Jones D, Sharma P, et al: Clinical and molecular phase II study of gefitinib in patients (pts) with recurrent squamous cell carcinoma of the head and neck (H&N Ca). J Clin Oncol 23:507s, 2005 (suppl, abstr 5531)
22. Kirby AM, A'Hern RP, D'Ambrosio C, et al: Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer. Br J Cancer 94:631-636, 2006
23. Soulieres D, Senzer NM, Vokes EE, et al: Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 22:77-85, 2004
24. Vermorken JB, Trigo J, Hitt R, et al: Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond platinum-based therapy. J Clin Oncol 25:2171-2177, 2007
25. Abidoye OO, Cohen EE, Wong SJ, et al: A phase II study of lapatinib (GW572016) in recurrent/ metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 24:297s, 2006 (suppl, abstr 5568)
26. Yang CH, Kies MS, Glisson B, et al: A phase II study of lonafarnib (SCH66336) in patients with chemo-refractory advanced head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 23:516s, 2005 (suppl, abstr 5565)
27. Choong NW, Cohen EE, Kozloff MF, et al: Phase II trial of sunitinib in patients with recurrent and. or metastatic squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 26:332s, 2008 (suppl; abstr 6064)
28. Fury MG, Zahalsky A, Wong R, et al: A phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Invest New Drugs 25:165-172, 2007
29. Williamson SK, MoonJ, Huang CH, et al: A phase II trial of sorafenib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC): A Southwest Oncology Group (SWOG) trial. J Clin Oncol 25:310s, 2007 (suppl; abstr 6044)
30. Elser C, Siu LL, Winquist E, et al: Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma. J Clin Oncol 25:3766-3773, 2007
31. Cohen EE, Davis DW, Karrison TG, et al: Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck. Lancet Oncol 10:247-257, 2009
32. Faivre S, Demetri G, Sargent W, et al: Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 6:734-745, 2007
33. Escudier B, Eisen T, Stadler WM, et al: Sorafenib in advanced clear-cell renal cell carcinoma. N Engl J Med 356:125-134, 2007
34. van der Veldt AA, Boven E, Helgason HH, et al: Predictive factors for severe toxicity in unselected patients with advanced renal cell cancer. Br J Cancer 99:259-265, 2008
35. Johnson DH, Fehrenbacher L, Novotny WF, et al: Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously locally advanced or metastatic non-small lung cancer. J Clin Oncol 22:2184-2191, 2004
36. Faivre S, Delbaldo C, Vera K, et al: Safety, pharmacokinetic, and first evidence of antitumor activity of SU11248, a novel oral multi-target tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol 24:25-35, 2006
37. Bates DO, Jones RO: The role of vascular endothelial growth factor in wound healing. Int J Low Extrem Wounds 2:107-120, 2003
38. Kamba T, McDonald DM: Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96:1788-1795, 2007
39. Anscher MS, Vujaskovic: Mechanisms and potential targets for prevention and treatment of normal tissue injury after radiation therapy. Semin Oncol 32:S86-S91, 2005 (suppl)
40. Roberts C, Issa B, Stone A, et al: Comparative study into the robustness of compartmental modeling and model-free analysis in DCE-MRI studies. J Magn Reson Imaging 23:554-563, 2006
41. Marzola P, Degrassi A, Calderan L, et al: Early antiangiogenic activity of SU11248 evaluated in vivo by Dynamic contrast-enhanced magnetic resonance imaging in an experimental model of colon carcinoma. Clin Cancer Res 11:5827-5832, 2005
42. Hahn OM, Yang C, Medved M, et al: Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal cell carcinoma. J Clin Oncol 26: 4572-4578, 2008
43. Flaherty KT, Rosen MA, Heitjan D, et al: Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma. Cancer Biol Ther 7:496-501, 2008